<p class="abstract"><strong>Background:</strong> Alopecia areata (AA) is a common auto-immune condition, causing hair loss. This disease has limited treatment modalities. Through this study, comparison between established modalities of treatment such as oral mini pulse therapy, intralesional corticosteroids and platelet-rich plasma (PRP) as a newer modality has been done. The objective of the study was to evaluate the efficacy and safety of various treatment modalities in alopecia areata.</p><p class="abstract"><strong>Methods:</strong> 45 patients with alopecia areata presenting to the OPD of Dermatology, Dhiraj hospital, Pipariya were included in this study. It was conducted as a randomized prospective study for a period of 16 weeks. After taking informed consent, patients were randomly distributed into three treatment groups. Group 1 patients were treated with Tab. Betamethasone 0.1 mg/kg every Saturday and Sunday, Group 2 was treated with Inj. Triamcinolone acetonide 10 mg/ml for scalp and 2.5 mg/ml for eye brows and face was injected into deep dermis; Group 3 was treated with Dermaroller followed by application of activated platelet rich plasma (PRP). SALT score was calculated at first visit and 16 weeks. Regrowth was calculated using Mac Donald and Null Horis grading Scale at 16 weeks.<strong></strong></p><p class="abstract"><strong>Results:</strong> The SALT score reduced from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2 and 42.32 to 21.12 in Group 3. Mean grade of regrowth of hairs observed was 3.47, 3.80, 2.93 in Group 1, 2, 3 respectively. The results were analysed using paired t test.</p><strong>Conclusions:</strong>Intralesional corticosteroids viz. triamcinolone acetonide still remains the first choice of therapy for AA in adults with limited involvement. Systemic corticosteroids give lower response than intralesional steroids. Platelet Rich Plasma (PRP) showed promising results, especially in children and in extensive involvement. Compared to other treatment modalities Inj. PRP is safe and with less side effects.<p> </p>
<p class="abstract"><strong>Background:</strong> The objective was to study various dermatological manifestations and clinical and laboratory features in patients of lupus erythematosus (LE) and its subsets.</p><p class="abstract"><strong>Methods:</strong> This is a cross sectional observational study done in a tertiary care hospital in a rural setup in Piparia, Ta. Waghodiya, Dist. Vadodara, Gujarat. All the patients with clinical features of LE and its subsets were included in the study over a period of 16 months and were subjected to detailed history taking, complete cutaneous and general examination and laboratory investigations.<strong></strong></p><p class="abstract"><strong>Results:</strong> Out of the 40 cases, 22 cases were systemic lupus erythematosus (SLE), 13 cases were discoid lupus erythematosus (DLE), four cases were of Rowell’s syndrome and one case was of mixed connective tissue disorder (MCTD). 97.5% of cases had cutaneous involvement, i.e. photosensitivity (77.5%), oral ulcers, hair loss and malar rash. Systemic symptoms and abnormal laboratory parameters were present in the cases of SLE, Rowell’s syndrome and MCTD, with hematological involvement being the most common in both SLE (77%) and Rowell’s syndrome (100%) and positive anti-nuclear antibody (ANA) titer being the most common abnormal laboratory finding in both SLE (95.4%) and Rowell’s syndrome (100%). The most commonly found antibody was anti-dsDNA (64.3%) in SLE and anti SS-A (100%) in Rowell’s syndrome.</p><p class="abstract"><strong>Conclusions:</strong> Cutaneous features though occasionally subtle, are pointers to a diagnosis of SLE. Hair loss, malar rash and photosensitivity alone or in association with altered hematologic/ANA profile are the key markers of the disease activity.</p><p> </p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.